Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: Are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2436-2457

  Behr, Thomas M ^a   Gratz, Stefan ^a   Markus, Peter M ^a   Dunn, Robert M ^b   Hüfner, Michael ^a   Schauer, Alfred ^a   Fischer, Manfred ^c   Munz, Dieter L ^d   Becker, Heinz ^a   Becker, Wolfgang ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^c City of Kassel   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Calcitonin; Carcinoembryonic antigen; Immunoscintigraphy; Medullary thyroid carcinoma; Monoclonal antibodies; Occult disease; Radioimmunotherapy; Somatostatin receptors

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY IN 111; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY I 125; PENTETREOTIDE IN 111; SUCCIMER TC 99M; TECHNETIUM 99M; THALLIUM CHLORIDE TL 201;

ADULT; AGED; ANTIGEN DETECTION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

EID: 0031459447     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2436::aid-cncr16>3.0.co;2-d     Document Type: Conference Paper

References (50)

1. Williams ED. Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol 1976;19:114-8.
2. Becker W, Spiegel W, Reiners Chr, Börner W. Besonderheiten bei der Nachsorge des C-Zell-Karzinons. Der Nuklearmediziner 1986;9:167-81.
3. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P, Pinchera A. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid cancer. J Clin Endocrinol Metab 1994;78:826-9.
4. Tisell LE, Hansson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986;99:60-6.
5. Tisell LE, Jansson S. Recent results of reoperative surgery in medullary carcinoma of the thyroid. Wien Klin Wochenschr 1988;100:347-8.
6. Wahl RA, Goretzki PE, Branscheid D, Vietmeier P, Röher HD. Reintervention beim C-Zell-Karzinom. Wien Klin Wochenschr 1988;100:348-51.
7. Tisell LE, Dilley WG, Wells SA. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery 1996;119:34-9.
8. van Heerden JA, Grand CS, Gharib H, Hay ID, Ilstrup DM. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid cancer. Ann Surg 1990;212:395-401.
9. Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 1988;67:801-8.
10. Ansari AN, Siegel ME, DeQuattro V, Gazarian LH. Imaging of medullary thyroid carcinoma and hyperfunctioning adrenal medulla using iodine-131 metaiodobenzylguanidine. J Nucl Med 1986;27:1858-60.
11. Dörr U, Würstlin S, Frank-Raue K, Raue F, Hehrmann R, Iser G, Scholz M, Guhl L, Buhr HJ, Bihl H. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study. In: Bihl H, Dörr U. Somatostatin receptor imaging (Hormone and metabolic research Suppl., Volume 27). Stuttgart: Thieme, 1993:48-55.
12. Frank-Raue K, Bihl H, Dörr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol 1995;42:31-7.
13. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, Bruining HA, Mulder AH, Oei HY. In vivo Somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993;76:1413-7.
14. Peltier P, Curtet C, Chatal JF, Le Doussal JM, Daniel G, Aillet G, et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 1993;34: 1267-73.
15. 131I-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 1995; 55:5946-51.
16. Juweid ME, Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic T, et al. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol 1996;14:1209-17.
17. Eising EG, Farahati J, Bier D, Knust EJ, Reiners C. Somatostatin-Rezeptorszintigraphie bei medullären Schilddrüsenkarzinomen, GEP-Tumoren und Karzinoiden. Nucl Med 199534:1-7.
18. Baudin E, Lumbruso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37:912-6.
19. Behr TM, Gratz S, Markus PM, Dunn RM, Hüfner M, Becker H, et al. Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumor manifestation? Eur J Nucl Med 1997;24:184-91.
20. 111In-labelled monoclonal anti-CEA antibody fragment. Nucl Med 1986;25:227-31.
21. Magnani P, Paganelli G, Songini C, Samuel A, Sudati F, Siccardi AG, et al. Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma. Br J Cancer 1996;74:825-31.
22. 131I-labeled anti-CEA antibodies. J Nucl Med 1996;37:875-81.
23. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Siegel JA, Goldenberg DM. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin monoclonal antibodies. J Nucl Med 1997;38:409-18.
24. 99mTc-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med 1995;36:430-41.
25. Primus FJ, Newell KD, Blue A, Goldenberg DM. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res 1983;43:686-92.
26. Schwarz A, Steinsträsser A. A novel approach to Tc-99m-labeled monoclonal antibodies. J Nucl Med 1987;28:721.
27. Weadock KS, Sharkey RM, Varga DC, Goldenberg DM. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 1990;31:508-11.
28. Dunn RM, Juweid ME, Behr TM, Siegel JA, Sharkey RM, Goldenberg DM. An automated internal dosimetry scheme for radiolabeled antibodies. Med Phys 1995;22:1549-50.
29. Behr TM, Dunn RM, Gratz S, Becker WS. An automated scheme for internal radiation dosimetry in nuclear therapy: gamma- or bremsstrahlung-based dose calculation in the therapy of differentiated thyroid cancer, radiosynoviorthesis, bone pain palliation and radioimmunotherapy [abstract]. Eur J Nucl Med 1996;23:1132.
30. Wu RK, Siegel JA. Absolute quantitation of radioactivity using the buildup factor. Med Phys 1984;11:189-92.
31. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37:538-46.
32. 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med 1996;23:1367-71.
33. Sandrock D, Steinröder M, Munz DL. Value of different scintigraphic methods in patients with medullary thyroid carcinoma [abstract]. J Nucl Med 1990;31:744-5.
34. Sandrock D, Munz DL. Diagnostik des medullären Schilddrüsenkarzinoms. Dtsch Med Wochenschr 1991;116:77-8.
35. 2 fragments of anticarcinoembiyonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma. J Clin Endocrinol Metab 1992;74:157-63.
36. Stoffel M, Jamar, Donckier J, Hainaut P, Decoster P, Beckers C, et al. Increased uptake of indium-111 pentetreotide up to 10 years after external thoracic irradiation: report of two cases. Eur J Nucl Med 1996;23:723-6.
37. Sharkey RM, Goldenberg DM, Goldenberg H, Lee RE, Ballance C, Pawlyk D, et al. Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic, and targeting properties in humans. Cancer Res 1990;50:2823-31.
38. Sharkey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawlyk D, et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 1993;71:2082-96.
39. Sharkey RM, Juweid M, Shevitz J, Behr TM, Dunn R, Swayne LC, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55:5935s-5945s.
40. Simon GH, Nitzsche EU, Laubenberger JJ, Einert A, Moser E. PET imaging of recurrent medullary thyroid cancer. Nucl Med 1996;35:102-4.
41. 18F-FDG-PET, MRT und CT in der Nachsorge des medullären Schilddrüsenkarzinoms [abstract]. Nucl Med 1996;35:A60.
42. Richter E, Feyerabend T. Normal lymph node topography: CT-atlas. Berlin: Springer, 1991.
43. Wegener OH. Ganzkörpercomputertomographie. Berlin: Blackwell Wissenschaft, 1992.
44. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991;64: 567-73.
45. O'Byrne KJ, O'Hare N, Sweeney E, Freyne PJ, Cullen MJ. Somatostatin and somatostatin analogues in medullary thyroid cancer. Nucl Med Commun 1996;17:810-6.
46. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, vanNagell JR, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection of and localization of diverse cancers by external photoscanning. N Engl J Med 1978;298:1384-88.
47. 99mTc-markierten Anti-CEA-Fab′-Fragemnten in der Nachsorge des kolorektalen Karzinoms: Chirurgische Resektabilitäts-Beurteilung aus der Kombination mit konventioneller Bildgebung. Dtsch Med Wochenschr 1997;122:463-70.
48. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Bosetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984;53:278-85.
49. Mendelsohn G, Wells SA Jr., Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. Cancer 1984;54:657-62.
50. 131I-labeled antibodies for radioimmunotherapy (RAIT) [abstract 21]. Tumor Targeting 1996; 2:145.